Literature DB >> 16584865

The detection of oesophageal adenocarcinoma by serum microsatellite analysis.

C F Eisenberger1, N H Stoecklein, S Jazra, S B Hosch, M Peiper, P Scheunemann, J Schulte Am Esch, W T Knoefel.   

Abstract

BACKGROUND AND AIMS: Organ-confined oesophageal cancer in an early stage can be cured in many patients, whereas more extensive lesions have a poor prognosis. We sought to develop a non-invasive test for cancer detection and evaluation of the prognosis of the patients by using a novel molecular approach.
MATERIAL AND METHODS: Matched normal-, tumour- and serum-samples were obtained from 32 patients with adenocarcinoma of the oesophagus. DNA was extracted and the samples were subjected to microsatellite analysis using 12 markers. Serum and normal samples from 10 healthy individuals served as controls.
RESULTS: Twenty-seven of the 32 patients (84.4%) with malignant tumours were found to have one or more microsatellite DNA alterations in their primary tumour. Twenty-six of the 32 patients (81.3%) had alterations in the serum by microsatellite analysis. Interestingly, all patients without lymphatic metastasis and three early carcinomas (pT1pN0) already displayed LOH alteration in the serum, while all serum DNA of samples from normal control subjects were negative. Survival was not significantly correlated with either LOH in the tumour or LOH in the serum.
CONCLUSION: These data suggest that microsatellite DNA analysis in serum specimens might provide a potentially valuable tool for early detection of oesophageal cancer. The evidence of circulating tumour DNA reflects the propensity of these tumours to spread to distant sites. Up to now the follow-up is still too short to draw further conclusions on the prognostic impact of this finding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584865     DOI: 10.1016/j.ejso.2006.02.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

Review 1.  Advances in the medical research and clinical applications on the plasma DNA.

Authors:  Shuye Wang; Yuanyuan Chen; Zhanhe Wu
Journal:  Transl Pediatr       Date:  2014-04

Review 2.  Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.

Authors:  Kristina Magaard Koldby; Michael Bau Mortensen; Sönke Detlefsen; Per Pfeiffer; Mads Thomassen; Torben A Kruse
Journal:  J Gastroenterol       Date:  2018-09-21       Impact factor: 7.527

Review 3.  Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers.

Authors:  K C A Chan; Y M D Lo
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

Review 4.  The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.

Authors:  Ian A Cree; Lesley Uttley; Helen Buckley Woods; Hugh Kikuchi; Anne Reiman; Susan Harnan; Becky L Whiteman; Sian Taylor Philips; Michael Messenger; Angela Cox; Dawn Teare; Orla Sheils; Jacqui Shaw
Journal:  BMC Cancer       Date:  2017-10-23       Impact factor: 4.430

Review 5.  The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers.

Authors:  Hariti Saluja; Christos S Karapetis; Susanne K Pedersen; Graeme P Young; Erin L Symonds
Journal:  Front Oncol       Date:  2018-07-24       Impact factor: 6.244

6.  Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients.

Authors:  Elisa Boldrin; Giorgia Nardo; Elisabetta Zulato; Laura Bonanno; Valentina Polo; Stefano Frega; Alberto Pavan; Stefano Indraccolo; Daniela Saggioro
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.